Goodwin advised BridgeBio Pharma on the matter. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Kyowa Kirin Co., Ltd (TSE:4151) announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics,...
You must be a Standard 1 Year member to access this content.
Goodwin advised OncoC4 on the deal. OncoC4 announced its agreement with BioNTech SE pursuant to which BioNTech receives an exclusive worldwide license to co-develop and commercialize OncoC4’s...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Lacerta Therapeutics on the deal. Lacerta Therapeutics announced its AAV capsid licensing and research collaboration agreement with Prevail Therapeutics. As a part of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Q32 Bio on the deal. Q32 Bio announced its collaboration and option agreement with Horizon Therapeutics Ireland DAC under which both companies will collaborate...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and...
You must be a Standard 1 Year member to access this content.
Goodwin advised Tessera Therapeutics on the deal. Tessera Therapeutics announced its collaboration with Serotiny to engineer programmable Gene Writer proteins. Under the terms of the agreement, Serotiny...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...
You must be a Standard 1 Year member to access this content.
